Name: Staphylococcus aureus CIP 106415
Creator: BacDive
License: https://creativecommons.org/licenses/by/4.0/

Strain identifier

BacDive ID: 138348

Type strain:

Species: Staphylococcus aureus

Culture col. no.: CIP 106415, ATCC 700698, CCUG 45316, Mu 3

Strain history: CIP <- 2000, P. Courvalin, Inst. Pasteur, Paris, France <- K. Hiramatsu, Tokyo, Japan: strain Mu3

NCBI tax ID(s): 1280 (species)

Special Collections

CCUG
CIP

Other strains from Staphylococcus aureus

Section

Staphylococcus aureus CIP 106415 is an aerobe, Gram-positive, coccus-shaped bacterium of the family Staphylococcaceae.

coccus-shaped
Gram-positive
aerobe
Bacteria
genome sequence

Information on the name and the taxonomic classification. Name and taxonomic classification

	Last LPSN update	14-12-2023 (DD-MM-YYYY)
	Domain	"Bacteria"
	Phylum	*Bacillota*
	Class	*Bacilli*
	Order	*Caryophanales*
	Family	*Staphylococcaceae*
	Genus	*Staphylococcus*
	Species	**Staphylococcus aureus**
	Full Scientific Name (LPSN)	Staphylococcus aureus Rosenbach 1884 (Approved Lists 1980)

Synonym

Staphylococcus aureus subsp. anaerobius

Information on morphological and physiological properties Morphology

[Ref.: #39515]	Gram stain	positive

[Ref.: #39515]	Cell shape	coccus-shaped

[Ref.: #39515]	Motility	no

Information on culture and growth conditions Culture and growth conditions

[Ref.: #39515]

Culture medium

MEDIUM 72- for trypto casein soja agar

[Ref.: #39515]

Culture medium growth

[Ref.: #39515]

Culture medium composition

expand / minimize

[Ref.: #39515]

Culture medium

CIP Medium 72

[Ref.: #39515]

Culture medium growth

[Ref.: #39515]

Culture medium link

Medium recipe provided by DSMZ

	Kind of temperature		Temperature
[Ref.: #39515]		growth	37 °C
[Ref.: #39515]		growth	22-45 °C
[Ref.: #39515]	no	growth	10 °C
[Ref.: #56732]		growth	37 °C

Information on physiology and metabolism Physiology and metabolism

[Ref.: #56732]	Oxygen tolerance	aerobe
[Ref.: #39515]	Oxygen tolerance	facultative anaerobe

	Metabolite	Utilization activity	Kind of utilization tested
[Ref.: #68375]	arabinose ChEBI	-	fermentation	* from API ID32STA
[Ref.: #68375]	arginine ChEBI	+	hydrolysis	* from API ID32STA
[Ref.: #68375]	cellobiose ChEBI	-	fermentation	* from API ID32STA
[Ref.: #68375]	D-fructose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	D-glucose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	D-mannitol ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	D-mannose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	D-ribose ChEBI	-	fermentation	* from API ID32STA
[Ref.: #68375]	esculin ChEBI	-	hydrolysis	* from API ID32STA
[Ref.: #39515]	hippurate ChEBI	+	hydrolysis
[Ref.: #68375]	lactose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	maltose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	N-acetylglucosamine ChEBI	+	fermentation	* from API ID32STA
[Ref.: #39515]	nitrate ChEBI	+	reduction
[Ref.: #68375]	nitrate ChEBI	+	reduction	* from API ID32STA
[Ref.: #39515]	nitrite ChEBI	-	reduction
[Ref.: #68375]	ornithine ChEBI	-	degradation	* from API ID32STA
[Ref.: #68375]	raffinose ChEBI	-	fermentation	* from API ID32STA
[Ref.: #68375]	sucrose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	trehalose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	turanose ChEBI	+	fermentation	* from API ID32STA
[Ref.: #68375]	urea ChEBI	-	hydrolysis	* from API ID32STA
	Only first 10 entries are displayed. Click here to see all.

	Antibiotica	Metabolite	Antibiotic sensitivity	Concentration
[Ref.: #68375]		novobiocin ChEBI	yes	1.8	µg	* from API ID32STA

	Metabolite production	Metabolite	Production
[Ref.: #39515]		indole ChEBI	no
[Ref.: #68375]		acetoin ChEBI	no	* from API ID32STA

	Physiological tests	Metabolite	Voges-Proskauer-test
[Ref.: #39515]		acetoin ChEBI	+
[Ref.: #68375]		acetoin ChEBI	-	* from API ID32STA

	Enzyme	Enzyme activity	EC number
[Ref.: #68382]	acid phosphatase	+	3.1.3.2	* from API zym
[Ref.: #39515]	alcohol dehydrogenase	-	1.1.1.1
[Ref.: #68375]	alkaline phosphatase	+	3.1.3.1	* from API ID32STA, API zym
[Ref.: #68382]	alpha-chymotrypsin	-	3.4.21.1	* from API zym
[Ref.: #68382]	alpha-fucosidase	-	3.2.1.51	* from API zym
[Ref.: #68382]	alpha-galactosidase	-	3.2.1.22	* from API zym
[Ref.: #68382]	alpha-glucosidase	+	3.2.1.20	* from API zym
[Ref.: #68382]	alpha-mannosidase	-	3.2.1.24	* from API zym
[Ref.: #39515]	amylase	-
[Ref.: #68375]	arginine dihydrolase	+	3.5.3.6	* from API ID32STA
[Ref.: #39515]	beta-galactosidase	+	3.2.1.23
[Ref.: #68375]	beta-galactosidase	-	3.2.1.23	* from API ID32STA, API zym
[Ref.: #68375]	beta-glucosidase	-	3.2.1.21	* from API ID32STA, API zym
[Ref.: #68375]	beta-glucuronidase	-	3.2.1.31	* from API ID32STA, API zym
[Ref.: #39515]	caseinase	+	3.4.21.50
[Ref.: #39515]	catalase	+	1.11.1.6
[Ref.: #39515]	coagulase	+
[Ref.: #68382]	cystine arylamidase	-	3.4.11.3	* from API zym
[Ref.: #39515]	DNase	+
[Ref.: #68382]	esterase (C 4)	+		* from API zym
[Ref.: #68382]	esterase lipase (C 8)	+		* from API zym
[Ref.: #39515]	gamma-glutamyltransferase	-	2.3.2.2
[Ref.: #39515]	gelatinase	-
[Ref.: #68375]	L-arginine arylamidase	-		* from API ID32STA
[Ref.: #39515]	lecithinase	-
[Ref.: #68382]	leucine arylamidase	+	3.4.11.1	* from API zym
[Ref.: #39515]	lipase	+
[Ref.: #68382]	lipase (C 14)	-		* from API zym
[Ref.: #39515]	lysine decarboxylase	-	4.1.1.18
[Ref.: #68382]	N-acetyl-beta-glucosaminidase	-	3.2.1.52	* from API zym
[Ref.: #68382]	naphthol-AS-BI-phosphohydrolase	+		* from API zym
[Ref.: #39515]	ornithine decarboxylase	-	4.1.1.17
[Ref.: #68375]	ornithine decarboxylase	-	4.1.1.17	* from API ID32STA
[Ref.: #39515]	oxidase	-
[Ref.: #39515]	phenylalanine ammonia-lyase	-	4.3.1.24
[Ref.: #39515]	protease	+
[Ref.: #68375]	pyrrolidonyl arylamidase	+	3.4.19.3	* from API ID32STA
[Ref.: #68382]	trypsin	-	3.4.21.4	* from API zym
[Ref.: #39515]	tween esterase	+
[Ref.: #39515]	urease	-	3.5.1.5
[Ref.: #68375]	urease	-	3.5.1.5	* from API ID32STA
[Ref.: #68382]	valine arylamidase	-		* from API zym
	Only first 10 entries are displayed. Click here to see all.

API® Biotype100:

Note that the displayed test results represent raw data and therefore may deviate!

	API ID	ControlQ	D-glucose as carbon sourceGLU	D-fructose as carbon sourceFRU	D-galactose as carbon sourceGAL	D-trehalose as carbon sourceTRE	D-mannose as carbon sourceMNE	L-sorbose as carbon sourceSBE	D-melibiose as carbon sourceMEL	sucrose as carbon sourceSAC	D-raffinose as carbon sourceRAF	maltotriose as carbon sourceMTE	maltose as carbon sourceMAL	lactose as carbon sourceLAC	lactulose as carbon sourceLTE	1-O-methyl-beta-galactopyranoside as carbon sourceMbGa	1-O-methyl-alpha-galactopyranoside as carbon sourceMaGa	D-cellobiose as carbon sourceCEL	gentiobiose as carbon sourceGEN	1-O-methyl-beta-D-glucopyranoside as carbon sourceMbGu	esculin as carbon sourceESC	D-ribose as carbon sourceRIB	L-arabinose as carbon sourceARA	D-xylose as carbon sourceXYL	palatinose as carbon sourcePLE	L-rhamnose as carbon sourceRHA	L-fucose as carbon sourceFUC	D-melezitose as carbon sourceMLZ	D-arabitol as carbon sourceDARL	L-arabitol as carbon sourceLARL	xylitol as carbon sourceXLT	dulcitol as carbon sourceDUL	D-tagatose as carbon sourceTAG	glycerol as carbon sourceGLY	myo-inositol as carbon sourceINO	D-mannitol as carbon sourceMAN	maltitol as carbon sourceMTL	D-turanose as carbon sourceTUR	D-sorbitol as carbon sourceSOR	adonitol as carbon sourceADO	hydroxyquinoline-beta-glucuronide as carbon sourceHBG	D-lyxose as carbon sourceLYX	i-erythritol as carbon sourceERY	1-O-methyl-alpha-D-glucoside as carbon sourceMDG	3-O-methyl-D-glucose as carbon source3MDG	D-saccharate as carbon sourceSAT	mucate as carbon sourceMUC	L-tartrate as carbon sourceLTAT	D-tartrate as carbon sourceDTAT	meso-tartrate as carbon sourceMTAT	D-malate as carbon sourceDMLT	L-malate as carbon sourceLMLT	cis-aconitate as carbon sourceCATE	trans-aconitate as carbon sourceTATE	tricarballylate as carbon sourceTTE	citrate as carbon sourceCIT	D-glucuronate as carbon sourceGRT	D-galacturonate as carbon sourceGAT	2-ketogluconate as carbon source2KG	5-ketogluconate as carbon source5KG	tryptophan as carbon sourceTRY	N-acetyl-D-glucosamine as carbon sourceNAG	D-gluconate as carbon sourceGNT	phenylacetate as carbon sourcePAC	protocatechuate as carbon sourcePAT	4-hydroxybenzoate as carbon sourcepOBE	quinate as carbon sourceQAT	gentisate as carbon sourceGTE	3-hydroxybenzoate as carbon sourcemOBE	benzoate as carbon sourceBAT	3-phenylpropionate as carbon sourcePPAT	m-coumarate as carbon sourceCMT	trigonelline as carbon sourceTGE	betaine as carbon sourceBET	putrescine as carbon sourcePCE	4-aminobutyrate as carbon sourceABT	histamine as carbon sourceHIN	DL-lactate as carbon sourceLAT	caprate as carbon sourceCAP	caprylate as carbon sourceCYT	L-histidine as carbon sourceHIS	succinate as carbon sourceSUC	fumarate as carbon sourceFUM	glutarate as carbon sourceGRE	DL-glycerate as carbon sourceGYT	5-aminovalerate as carbon sourceAVT	ethanolamine as carbon sourceETN	tryptamine as carbon sourceTTN	D-glucosamine as carbon sourceGLN	itaconate as carbon sourceITA	3-hydroxybutyrate as carbon source3OBU	L-aspartate as carbon sourceAPT	L-glutamate as carbon sourceGTT	L-proline as carbon sourcePRO	D-alanine as carbon sourceDALA	L-alanine as carbon sourceLALA	L-serine as carbon sourceSER	malonate as carbon sourceMNT	propionate as carbon sourcePROP	L-tyrosine as carbon sourceTYR	2-ketoglutarate as carbon source2KT
[Ref.: #39515]	1674	not determinedn.d.	+	+	+	+	+	-	-	+	-	+	+	+	+	-	-	-	-	+	-	+	-	-	-	-	-	-	+	-	-	-	-	+	-	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	+	+	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	+	+	-	-	-	-	-	+	-	-	+	+	+	-	-	+	-	-	-	+

API® ID32STA:

Note that the displayed test results represent raw data and therefore may deviate!

	API ID	Urease/urea hydrolysisURE	Arginine dihydrolaseADH (Arg)	Ornithine decarboxylaseODC	Esculin hydrolysisESC	Fermentation of D-glucoseGLU	Fermentation of D-fructoseFRU	Fermentation of D-mannoseMNE	Fermentation of maltoseMAL	Fermentation of lactoseLAC	Fermentation of trehaloseTRE	Fermentation of D-mannitolMAN	Fermentation of raffinoseRAF	Fermentation of D-riboseRIB	Fermentation of cellobioseCEL	Reduction of nitrateNIT	Acetoin production (Voges Proskauer test)VP	beta-Galactosidasebeta GAL	L-arginine arylamidaseArgA	Alkaline phosphatasePAL	Pyrrolidonyl arylamidasePyrA	Novobiocin resistanceNOVO	Fermentation of sucroseSAC	Fermentation of N-acetyl-glucosamineNAG	Fermentation of turanoseTUR	Fermentation of arabinoseARA	beta-Glucuronidasebeta GUR
[Ref.: #56732]	2246	-	+	-	-	+	+	+	+	+	+	+	-	-	-	+	-	-	-	+	+	-	+	+	+	-	-

API® zym:

Note that the displayed test results represent raw data and therefore may deviate!

	API ID	Control	2-naphthyl phosphateAlkaline phosphatase	2-naphthyl butyrateEsterase (C 4)	2-naphtyl caprylateEsterase Lipase (C 8)	2-naphthyl myristateLipase (C 14)	L-leucyl-2-naphthylamideLeucine arylamidase	L-valyl-2-naphthylamideValine arylamidase	L-cystyl-2-naphthylamideCystine arylamidase	N-benzoyl-DL-arginine-2-naphthylamideTrypsin	N-glutaryl-phenylalanine-2-naphthylamidealpha- Chymotrypsin	2-naphthyl phosphateAcid phosphatase	Naphthol-AS-BI-phosphateNaphthol-AS-BI-phosphohydrolase	6-Br-2-naphthyl-alphaD-galactpyranosidealpha- Galactosidase	2-naphthyl-betaD-galactpyranosidebeta- Galactosidase	Naphthol-AS-BI-betaD-glucuronidebeta- Glucuronidase	2-naphthyl-alphaD-glucopyranosidealpha- Glucosidase	6-Br-2-naphthyl-betaD-glucopyranosidebeta- Glucosidase	1-naphthyl-N-acetyl-betaD-glucosaminideN-acetyl-beta- glucosaminidase	6-Br-2-naphthyl-alphaD-mannopyranosidealpha- Mannosidase	2-naphthyl-alphaL-fucopyranosidealpha- Fucosidase
[Ref.: #39515]	9481	-	+	+	+	-	+	-	-	-	-	+	+	-	-	-	+	-	-	-	-

Information on isolation source, the sampling and environmental conditions Isolation, sampling and environmental information

[Ref.: #56732]	Sample type/isolated from	Human lung
[Ref.: #56732]	Country	Japan
[Ref.: #56732]	Country ISO 3 Code	JPN
[Ref.: #56732]	Continent	Asia

[Ref.: #39515]	Sample type/isolated from	Human, Lung
[Ref.: #39515]	Country	Japan
[Ref.: #39515]	Country ISO 3 Code	JPN
[Ref.: #39515]	Continent	Asia

[Ref.: #39515]	Country	Japan
[Ref.: #39515]	Country ISO 3 Code	JPN
[Ref.: #39515]	Continent	Asia
* marker position based on {}

Isolation sources categories

#Host	#Human	-
#Host Body-Site	#Oral cavity and airways	#Lung

What are isolation sources categories?

Information on possible application of the strain and its possible interaction with e.g. potential hosts Safety information

[Ref.: #39515]

Biosafety level

Risk group (French classification)

Information on genomic background e.g. entries in nucleic sequence databass Sequence information

Genome sequence information:

	Sequence accession description	Seq. accession number	Assembly level	Sequence database	Associated NCBI tax ID
[Ref.: #66792]	Staphylococcus aureus strain NRS2	1280.4823	wgs	PATRIC	1280 tax ID	*

Data predicted using genome information as a basis Genome-based predictions

	Trait	Model	Prediction	Confidence in %	In training data
	Predictions from GenomeNet Sporulation v. 1 based on: Staphylococcus aureus strain NRS2 PATRIC: 1280.4823
[Ref.: #69481]	spore-forming	spore-formingⓘ	no	83	no

	Trait	Model	Prediction	Confidence in %	In training data
	Predictions from Diaspora project based on: Staphylococcus aureus strain NRS2 PATRIC: 1280.4823
[Ref.: #69480]	gram-positive	gram-positiveⓘ	yes	85.222	no
[Ref.: #69480]	anaerobic	anaerobicⓘ	no	99.437	yes
[Ref.: #69480]	spore-forming	spore-formingⓘ	no	71.666	no
[Ref.: #69480]	aerobic	aerobicⓘ	yes	55.147	no
[Ref.: #69480]	thermophilic	thermophileⓘ	no	94.24	yes
[Ref.: #69480]	flagellated	motile2+ⓘ	no	80.887	no

Availability in culture collections External links

[Ref.: #39515]

Culture collection no.

CIP 106415, ATCC 700698, CCUG 45316, Mu 3

Literature:

Only first 10 entries are displayed. Click here to see all.

Topic	Title	Authors	Journal	DOI	Year
Pathogenicity	Efficacy and mechanism of carvacrol with octanoic acid against mastitis causing multi-drug-resistant pathogens.	Rani S, Singh H, Ram C	Braz J Microbiol	10.1007/s42770-021-00639-4	2021	*
Phenotype	Variable Release of Lipoteichoic Acid From Staphylococcus aureus Bloodstream Isolates Relates to Distinct Clinical Phenotypes, Strain Background, and Antibiotic Exposure.	Algorri M, Jorth P, Wong-Beringer A	Front Microbiol	10.3389/fmicb.2020.609280	2021	*
Pathogenicity	Differentiation of qacA and qacB using high-resolution melt curve analysis, and both qacA and qacB but not qacC or norA types increase chlorhexidine minimal inhibitory concentrations in Staphylococcus aureus isolates.	Lin KH, Lin CY, Huang CC, Ho YL, Yang SF, Ho CM	J Microbiol Immunol Infect	10.1016/j.jmii.2020.09.006	2020	*
Enzymology	Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.	Kim HK, Choi SM, Kang G, Park KH, Lee DG, Park WB, Rhee SJ, Lee S, Jung SI, Jang HC	Yonsei Med J	10.3349/ymj.2020.61.4.301	2020	*
Pathogenicity	Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models.	Ohsawa H, Baba T, Enami J, Hiramatsu K	J Infect Chemother	10.1016/j.jiac.2019.12.018	2020	*
Pathogenicity	VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance.	Gao C, Dai Y, Chang W, Fang C, Wang Z, Ma X	Microbes Infect	10.1016/j.micinf.2019.04.003	2019	*
Pathogenicity	Identification of a Novel Gene Associated with High-Level beta-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315.	Matsuo M, Yamamoto N, Hishinuma T, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00712-18	2019	*
Pathogenicity	Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.	Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B	Antimicrob Agents Chemother	10.1128/AAC.02100-17	2018	*
Pathogenicity	Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.	Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF	Antimicrob Agents Chemother	10.1128/AAC.00452-17	2017	*
Pathogenicity	VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.	Dai Y, Chang W, Zhao C, Peng J, Xu L, Lu H, Zhou S, Ma X	Antimicrob Agents Chemother	10.1128/AAC.02740-16	2017	*
Pathogenicity	Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.	Lai CC, Chen CC, Chuang YC, Tang HJ	Sci Rep	10.1038/srep41758	2017	*
Transcriptome	Complete sequence of a plasmid from a bovine methicillin-resistant Staphylococcus aureus harbouring a novel ica-like gene cluster in addition to antimicrobial and heavy metal resistance genes.	Fessler AT, Zhao Q, Schoenfelder S, Kadlec K, Brenner Michael G, Wang Y, Ziebuhr W, Shen J, Schwarz S	Vet Microbiol	10.1016/j.vetmic.2016.07.010	2016	*
Metabolism	Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.	Katayama Y, Sekine M, Hishinuma T, Aiba Y, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00420-16	2016	*
Pathogenicity	Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.	Khatib R, Riederer K, Sharma M, Shemes S, Iyer SP, Szpunar S	J Clin Microbiol	10.1128/JCM.01620-15	2015	*
Pathogenicity	Adaptation to vancomycin pressure of multiresistant Staphylococcus capitis NRCS-A involved in neonatal sepsis.	Butin M, Martins-Simoes P, Picaud JC, Kearns A, Claris O, Vandenesch F, Laurent F, Rasigade JP	J Antimicrob Chemother	10.1093/jac/dkv217	2015	*
Pathogenicity	Exposure of Staphylococcus aureus to subinhibitory concentrations of beta-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.	Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydiere AM, Laurent F, Reix P, Dumitrescu O, Vandenesch F	Antimicrob Agents Chemother	10.1128/AAC.02574-14	2014	*
Phenotype	"Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.	Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, Cui L, Matsuo M, Aritaka N, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.02470-13	2014	*
Pathogenicity	Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.	Matsuo M, Cui L, Kim J, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00425-13	2013	*
Phylogeny	Global analysis of transcriptional regulators in Staphylococcus aureus.	Ibarra JA, Perez-Rueda E, Carroll RK, Shaw LN	BMC Genomics	10.1186/1471-2164-14-126	2013	*
Phenotype	Presence of both heterogeneous vancomycin-intermediate resistance and beta-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.	Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H, Matsunaga A, Nishida T, Ishikura H, Ishikawa T, Tamura K, Tsuji BT	Scand J Infect Dis	10.3109/00365548.2012.723221	2012	*
Pathogenicity	Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.	Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00398-11	2011	*
Phylogeny	Sequence diversities of serine-aspartate repeat genes among Staphylococcus aureus isolates from different hosts presumably by horizontal gene transfer.	Xue H, Lu H, Zhao X	PLoS One	10.1371/journal.pone.0020332	2011	*
Pathogenicity	Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.	Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S	J Antimicrob Chemother	10.1093/jac/dkr169	2011	*
Pathogenicity	Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.	Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R	J Clin Microbiol	10.1128/JCM.01435-10	2011	*
Pathogenicity	Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.	Satola SW, Farley MM, Anderson KF, Patel JB	J Clin Microbiol	10.1128/JCM.01128-10	2010	*
Pathogenicity	First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.	Al-Obeid S, Haddad Q, Cherkaoui A, Schrenzel J, Francois P	J Clin Microbiol	10.1128/JCM.00954-09	2010	*
Pathogenicity	Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.	Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM	J Antimicrob Chemother	10.1093/jac/dkq028	2010	*
Pathogenicity	Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.	Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, Mayall BC, Johnson PD, Grayson ML	Antimicrob Agents Chemother	10.1128/AAC.01365-08	2009	*
Genetics	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.	Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00834-08	2009	*
Pathogenicity	Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.	Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM	J Antimicrob Chemother	10.1093/jac/dkp001	2009	*
Enzymology	Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.	Leonard SN, Rybak MJ	J Antimicrob Chemother	10.1093/jac/dkn439	2008	*
Pathogenicity	Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital.	Iyer RN, Hittinahalli V	Indian J Med Microbiol	10.4103/0255-0857.40537	2008	*
Pathogenicity	The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin.	Oshiro T, Nagasawa Z, Hanaki H, Ikeda-Dantsuji Y, Nagayama A	J Infect Chemother	10.1007/s10156-007-0569-9	2008	*
Pathogenicity	Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus.	Amiali NM, Mulvey MR, Berger-Bachi B, Sedman J, Simor AE, Ismail AA	J Antimicrob Chemother	10.1093/jac/dkm400	2007	*
Pathogenicity	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.	Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.00534-07	2007	*
Pathogenicity	Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50.	Utaida S, Pfeltz RF, Jayaswal RK, Wilkinson BJ	Antimicrob Agents Chemother	10.1128/AAC.50.4.1541-1545.2006	2006	*
Pathogenicity	[The combined effect of methicillin and teicoplanin against Staphylococcus aureus strains investigated in vitro].	Mlynarczyk A, Mlynarczyk G, Luczak M	Med Dosw Mikrobiol		2005	*
Transcriptome	A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.	McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA	Antimicrob Agents Chemother	10.1128/AAC.49.5.1865-1871.2005	2005	*
Pathogenicity	Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.	Nonhoff C, Denis O, Struelens MJ	Clin Microbiol Infect	10.1111/j.1469-0691.2004.01060.x	2005	*
Pathogenicity	In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci.	Bergeret M, Boutros N, Raymond J	Int J Antimicrob Agents	10.1016/j.ijantimicag.2003.08.009	2004	*
Metabolism	Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315.	Ohta T, Hirakawa H, Morikawa K, Maruyama A, Inose Y, Yamashita A, Oshima K, Kuroda M, Hattori M, Hiramatsu K, Kuhara S, Hayashi H	DNA Res	10.1093/dnares/11.1.51	2004	*
Pathogenicity	[Epidemiological investigation of MRSA with antagonistic effects of beta-lactam antibiotic and vancomycin].	Yamaguchi Y, Hanaki H, Barada K, Inamatu T, Sunakawa K	Kansenshogaku Zasshi	10.11150/kansenshogakuzasshi1970.77.661	2003	*
Pathogenicity	Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA).	Kim YS, Kiem S, Yun HJ, Jung SI, Oh WS, Kim SW, Peck KR, Lee NY, Song JH	J Korean Med Sci	10.3346/jkms.2003.18.3.319	2003	*
Pathogenicity	Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin.	Haraga I, Nomura S, Fukamachi S, Ohjimi H, Hanaki H, Hiramatsu K, Nagayama A	Int J Infect Dis	10.1016/s1201-9712(02)90165-7	2002	*
Pathogenicity	Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.	Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, Tanimoto K, Fujimoto S	J Clin Microbiol	10.1128/JCM.39.12.4445-4451.2001	2001	*
Pathogenicity	[Investigation of infective endocarditis clinical isolates of methicillin resistant Staphylococcus aureus non-responsive to vancomycin].	Takayama Y, Yoshida K, Yamaguchi Y, Nonoyama M, Endo T, Sunakawa K	Kansenshogaku Zasshi	10.11150/kansenshogakuzasshi1970.75.473	2001	*
Pathogenicity	Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.	Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D	J Clin Microbiol	10.1128/JCM.39.7.2439-2444.2001	2001	*
Pathogenicity	[Clinical relevance of hetero-VRSA in surgical infections].	Okii K, Takesue Y, Yokoyama T	Nihon Rinsho		2001	*
Pathogenicity	A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.	Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP	J Antimicrob Chemother	10.1093/jac/47.4.399	2001	*
Pathogenicity	Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.	Aritaka N, Hanaki H, Cui L, Hiramatsu K	Antimicrob Agents Chemother	10.1128/AAC.45.4.1292-1294.2001	2001	*
Metabolism	A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.	Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS	Antimicrob Agents Chemother	10.1128/AAC.45.1.280-287.2001	2001	*
Phylogeny	Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method.	Kuroda M, Kuwahara-Arai K, Hiramatsu K	Biochem Biophys Res Commun	10.1006/bbrc.2000.2277	2000	*
Cultivation	[A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (hetero-VRSA)].	Hanaki H, Inaba Y, Sasaki K, Hiramatsu K	Jpn J Antibiot		1998	*
Metabolism	Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.	Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K	J Antimicrob Chemother	10.1093/jac/42.3.315	1998	*
Metabolism	Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.	Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K	J Antimicrob Chemother	10.1093/jac/42.2.199	1998	*
Pathogenicity	The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.	Hiramatsu K	Am J Med	10.1016/s0002-9343(98)00149-1	1998	*
Pathogenicity	Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure.	Gaillard T, Dupieux-Chabert C, Butin M, Dumitrescu O, Naceur O, Bouveyron C, Martra A, Bes M, Tristan A, Vandenesch F, Lina G, Laurent F, Rasigade JP	J Antimicrob Chemother	10.1093/jac/dkab488	2022	*
	Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Uses the VraSR Regulatory System to Modulate Autophagy for Increased Intracellular Survival in Macrophage-Like Cell Line RAW264.7.	Dai Y, Gao C, Chen L, Chang W, Yu W, Ma X, Li J	Front Microbiol	10.3389/fmicb.2019.01222	2019	*
	Detection Methods for Glycopeptide-Resistant Staphylococcus aureus II : Cell Wall Analysis.	Hanaki H, Hiramatsu K	Methods Mol Med	10.1385/1-59259-077-2:93	2001	*
	Detection Methods of Glycopeptide-Resistant Staphylococcus aureus I : Susceptibility Testing.	Hanaki H, Hiramatsu K	Methods Mol Med	10.1385/1-59259-077-2:85	2001	*
	Subinhibitory Concentrations of Antibiotics Exacerbate Staphylococcal Infection by Inducing Bacterial Virulence.	Gao P, Wei Y, Wan RE, Wong KW, Iu HTV, Tai SSC, Li Y, Yam HCB, Halebeedu Prakash P, Chen JHK, Ho PL, Yuen KY, Davies J, Kao RYT	Microbiol Spectr	10.1128/spectrum.00640-22	2022	*

References

#20215

Parte, A.C., Sardà Carbasse, J., Meier-Kolthoff, J.P., Reimer, L.C. and Göker, M.: List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. IJSEM ( DOI 10.1099/ijsem.0.004332 )

#39515 Collection of Institut Pasteur ; Curators of the CIP; CIP 106415
#56732 Culture Collection University of Gothenburg (CCUG) ; Curators of the CCUG; CCUG 45316

#66792

Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg Overmann: Automatically annotated for the DiASPora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information) .

#68375

Automatically annotated from API ID32STA .

#68382

Automatically annotated from API zym .

#69480

Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg Overmann: Predictions based on genome sequence made in the Diaspora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information) .

#69481

Xiao-Yin To, René Mreches, Martin Binder, Alice C. McHardy, Philipp C. Münch: Predictions based on the model GenomeNet Sporulation v. 1 . ( DOI 10.21203/rs.3.rs-2527258/v1 )

* These data were automatically processed and therefore are not curated

Change proposal

You found an error in BacDive? Please tell us about it!

Note that changes will be reviewed and judged. If your changes are legitimate, changes will occur within the next BacDive update. Only proposed changes supported by the according reference will be reviewed. The BacDive team reserves the right to reject proposed changes.

Search for species Staphylococcus aureus in external resources:
SILVA
BRENDA
PANGAEA
GBIF

Staphylococcus aureus strain NRS2

Staphylococcus aureus strain NRS2

Change proposal

Change proposal